Altimmune (ALT) Competitors

ANI Pharmaceuticals (NASDAQ:ANIP) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, community ranking, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Which has more risk & volatility, ANIP or ALT?

ANI Pharmaceuticals has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.

Which has preferable earnings & valuation, ANIP or ALT?

ANI Pharmaceuticals has higher revenue and earnings than Altimmune. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$614.38M	2.51	$18.78M	-$1.14	-62.01
Altimmune	$20K	19,908.12	-$88.45M	-$1.34	-3.86

Do insiders and institutionals hold more shares of ANIP or ALT?

76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 11.1% of ANI Pharmaceuticals shares are held by insiders. Comparatively, 4.1% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Does the media favor ANIP or ALT?

In the previous week, ANI Pharmaceuticals had 2 more articles in the media than Altimmune. MarketBeat recorded 8 mentions for ANI Pharmaceuticals and 6 mentions for Altimmune. ANI Pharmaceuticals' average media sentiment score of 1.05 beat Altimmune's score of 0.77 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ANIP or ALT more profitable?

ANI Pharmaceuticals has a net margin of -1.28% compared to Altimmune's net margin of -199,076.92%. ANI Pharmaceuticals' return on equity of 15.87% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	-1.28%	15.87%	6.88%
Altimmune	-199,076.92%	-55.81%	-50.60%

Does the MarketBeat Community prefer ANIP or ALT?

ANI Pharmaceuticals received 378 more outperform votes than Altimmune when rated by MarketBeat users. However, 72.94% of users gave Altimmune an outperform vote while only 64.14% of users gave ANI Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
ANI Pharmaceuticals	Outperform Votes 440 64.14%	Underperform Votes 246 35.86%
Altimmune	Outperform Votes 62 72.94%	Underperform Votes 23 27.06%

Do analysts recommend ANIP or ALT?

ANI Pharmaceuticals presently has a consensus price target of $80.13, indicating a potential upside of 13.35%. Altimmune has a consensus price target of $20.83, indicating a potential upside of 302.97%. Given Altimmune's higher probable upside, analysts plainly believe Altimmune is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Altimmune	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

ANI Pharmaceuticals beats Altimmune on 11 of the 17 factors compared between the two stocks.